Viral vector-mediated gene transfer to the postnatal respiratory epithelium has, in general, been of low efficiency due to physical and immunological barriers, non-apical location of cellular receptors critical for viral uptake and limited transduction of resident stem/progenitor cells. These obstacles may be overcome using a prenatal strategy. In this study, HIV-1-based lentiviral vectors (LVs) pseudotyped with the envelope glycoproteins of Jaagsiekte sheep retrovirus (JSRV-LV), baculovirus GP64 (GP64-LV), Ebola Zaire-LV or vesicular stomatitis virus (VSVg-LV) and the adeno-associated virus-2/6.2 (AAV2/6.2) were compared for in utero transfer of a green fluorescent protein (GFP) reporter gene to ovine lung epithelium between days 65 and 78 of gestation. GFP expression was examined on day 85 or 136 of gestation (term is B145 days). The percentage of the respiratory epithelial cells expressing GFP in fetal sheep that received the JSRV-LV (3.18Â10 8 -6.85Â10 9 viral particles per fetus) was 24.6 ± 0.9% at 3 weeks postinjection (day 85) and 29.9±4.8% at 10 weeks postinjection (day 136). Expression was limited to the surface epithelium lining fetal airways o100 mm internal diameter. Fetal airways were amenable to VSVg-LV transduction, although the percentage of epithelial expression was low (6.6 ± 0.6%) at 1 week postinjection. GP64-LV, Ebola Zaire-LV and AAV2/6.2 failed to transduce the fetal ovine lung under these conditions. These data demonstrate that prenatal lung gene transfer with LV engineered to target apical surface receptors can provide sustained and high levels of transgene expression and support the therapeutic potential of prenatal gene transfer for the treatment of congenital lung diseases.
INTRODUCTION
Viral-mediated gene transfer to the lung holds considerable promise for therapeutic management of life-threatening inherited disorders including cystic fibrosis and surfactant protein B (SP-B) deficiency. Efficient gene transfer to the mature respiratory epithelium presents a formidable challenge due to a spectrum of obstacles, including airway mucous and cilia, extracellular glycoproteins (that is glycocalyx) and pulmonary macrophages. [1] [2] [3] [4] [5] [6] Another significant obstacle to viral vector gene transfer is the gradual loss of lung transduction due to constant turnover of differentiated respiratory epithelium. 7 Transduction of lung epithelial stem/progenitor cells using adeno-associated virus (AAV) can achieve sustained levels (up to 6 months) of transgene expression; however, chemical injury of the lung is necessary before vector administration. 8 Without the ability to transduce high numbers of stem/progenitor cells using less invasive approaches, life-long diseases such as cystic fibrosis and SP-B deficiency may require repeated administrations of viral vector to maintain therapeutic levels of transgene expression. However, re-administration of the same vector leads to production of neutralizing antibodies that block lung transduction. 7, 9 Many of the obstacles to postnatal lung gene transfer can potentially be avoided by a prenatal approach. During mid-gestation, the fetal airways are predominantly non-ciliated, 10 devoid of mucous 11 (sheep studies) and macrophages (rat study), 12 and the glycocalyx has yet to fully develop (human studies). 13, 14 More importantly, compared with the adult lung, the proportion of airway epithelial stem/progenitor cells is highest during fetal life where they are undergoing rapid proliferation and expansion. As a point of reference, during the pseudoglandular stage of lung development in sheep, which occurs between days 60 and 80 of gestation (term is B145 days), airway number and surface area increase by B400% and 127%, respectively (data from the current study). Fetal lung gene transfer can also take advantage of the immature immune system of the fetus. During early gestation while the thymus is processing self-antigen, the fetal immune system can be made tolerant to foreign antigen. In mice, immunological tolerance to viral vector and transgene following in utero gene therapy has provided life-long and stable expression of transgene 15, 16 and theoretically, may enable re-administration of the same vector after birth without eliciting an adaptive immune response.
Early proof-of-principle animal studies employed adenovirus for gene transfer to the fetal lung; [17] [18] [19] however, transgene expression was transient and resulted in production of anti-adenovirus antibodies. AAV vectors have achieved long-term transgene expression in non-human primates (up to 24 months) 20 but only short-term expression, up to 24 days, in rabbits 21 following in utero delivery. In adult mice, AAV efficiently transduced respiratory epithelium for up to 9 months, although a steady decline in transgene expression was reported. 22 Because AAV vectors designed for gene therapy have a low frequency of integration into the host genome, transgene expression is gradually lost through cell division. Another major drawback of AAV vectors is their limited packaging capacity (B4.7 Kb), which precludes insertion of some full-length therapeutic genes required to treat lung diseases such as cystic fibrosis and SP-B deficiency. In contrast, HIV-1-based lentiviral vectors (LVs) have increased packaging capacity (optimal transgene insert B5-7 Kb 23 ) and, following in utero delivery, are able to integrate into the host genome to provide life-long stable transgene expression. 16, [24] [25] [26] [27] Fetal lung gene transfer has been investigated in non-human primates, 20, 28 rabbits, 29 rats 30, 31 and sheep 32 using vesicular stomatitis virus glycoprotein (VSVg) pseudotyped LV. Long-term luciferase transgene expression (that is 12-15 months after fetal gene transfer) has been reported 31, 33 although there is a paucity of quantitative information on degree of epithelial transduction and cell types transduced. In sheep, VSVg-LV injected into the fetal airways between days 75 and 77 achieved limited airway epithelial transduction. 32 The receptor for VSVg is thought to be located on the basolateral surface of the respiratory epithelium, 34, 35 which may explain, in part, inefficient gene transfer to the fetal respiratory epithelium in sheep. 32 Designing pseudotyped LV to target airway epithelial surface receptors is an effective strategy to enhance lung gene transfer. [36] [37] [38] To determine whether a lung-targeting vector would efficiently transduce fetal sheep airways, we developed a LV pseudotyped with the envelope glycoprotein of the Jaagsiekte sheep retrovirus (JSRV). JSRV utilizes the airway epithelial cell-surface receptor hyaluronidase-2 (HYAL2) for cell entry. 39 Compared with other species, mid-gestation sheep are ideally suited for preclinical studies of fetal lung gene therapy because (1) up to day 80 of gestation, structural development and epithelial differentiation is remarkably similar to that of equivalent stage human fetuses; 10 (2) they are surgically amenable to simultaneous intra-tracheal vector injection and tracheal occlusion; this strategy effectively 'traps' vector within the airway to increase transduction time. Performing these procedures during the midpseudoglandular stage in rodents (that is BE15) is technically challenging, due to the small size of the fetus, although it has been achieved in fetal mice at E18; 40 and (3) sheep have a long gestation compared with rodents and rabbits, which permits analysis of lung gene expression across subsequent stages of fetal lung development.
The development of a model of airway epithelial stem/progenitor cell transduction during early stages of lung development would have important clinical therapeutic implications but may also be useful in defining mechanisms of lung development in health and disease. In this study, we compare the lung targeted viral vectors, specifically JSRV-LV, baculovirus GP64-LV, 36 Ebola (Zaire strain)-LV 37 and AAV2/ 6.2 (refs 31, 41) for their ability to achieve prenatal gene transfer to lung epithelium.
RESULTS
HYAL2 ontogeny and localization in fetal sheep lung HYAL2, the cell-surface binding receptor for JSRV, is present within ovine lung although no information exists on its expression and/or airway epithelial localization in developing fetal sheep. As determined by western immunoblotting, a single band was observed between 50 and 55 kDa with an expected size for HYAL2, based upon amino-acid sequence, of 52 kDa (Figure 1 ). During the canalicular stage of lung development (80-120 days), pulmonary HYAL2 expression decreased by 39.6%. At term (145 days), lung levels of HYAL2 expression were 61.9% lower than that at 80 days. At 65 days of gestation, which approximates the age at which JSRV-lentivirus was injected, cytoplasmic HYAL2 expression in cartilaginous trachea was restricted to basal cells and ciliated columnar epithelium; in the later cell type, HYAL2 expression was highest below the apical membrane ( Figure 1 ). HYAL2 staining was absent from tracheal non-ciliated columnar epithelium. In distal airways (25-100 mm), epithelial HYAL2 was highest at the apical surface. HYAL2 was not present when primary antibody was omitted from the immunostaining protocol (data not shown).
Screening for exogenous gene expression after mid-gestation fetal lung gene transfer The presence of green fluorescent protein (GFP) was evaluated in nine fetal sheep that underwent intra-tracheal injection of viral vector with tracheal occlusion as detailed in Table 1 .
JSRV-pseudotyped LV. When injected at 78 days gestational age and evaluated at 85 days, pulmonary epithelial GFP was detected in 93.9% (175 of 187) of distal airways with internal diameters (IDs) between 20 and 80 mm, with an average of 15.8 ± 0.7% of epithelial cells expressing GFP. When injected at 65 days and evaluated at 85 days of gestation, JSRV transduced 94.5% (69 of 73) of distal airways (20-80 mm ID), with an average of 24.6 ± 0.9% of epithelial cells expressing GFP (Figure 2 ). GFP signal was highest at distal tips of developing airways as determined via stereoscopic fluorescent microscopy ( Figure 3 ). GFP immunostaining was absent from airways with an ID 4100 mm. In two fetal lambs, JSRV-LV was administered at 65 days and GFP expression evaluated at 136 days gestational age. In these animals, of the 38 distal airways that met inclusion criteria for quantitative Figure 1 Pulmonary expression of HYAL2, the surface receptor for JSRV. Western immunoblotting (50 mg total protein loaded per lane) demonstrates an increase HYAL2 expression with decreasing gestational age. At day 78, HYAL2 is present within ciliated epithelium (indicated with arrows) of larger airways (trachea shown), while staining is absent from non-ciliated serous cells. In distal airways, HYAL2 is located on the apical epithelial surface.
analysis (B25% of airways per section), all were positive for GFP immunostaining, with an average epithelial expression of 28.4 ± 2.5% (100-300 mm ID). Irrespective of injection protocol, pleural lymphatics, located within the junction of interlobular septa, and paravertebral lymph nodes were positive for GFP signal ( Figure 4 ). Fetal hepatic GFP immunostaining was also observed, albeit at low frequency (1-3 cells per cm 2 ). Other major fetal organs, amniotic membranes, placental tissue and maternal liver were negative for GFP.
VSVg protein-pseudotyped LV. When injected at 70 days gestational age and evaluated at 78 days, GFP was present in 37.7% (34 of 90) distal airways with ID between 20 and 110 mm; average epithelial expression of GFP was 6.6 ± 0.6% ( Figure 2 ). Unlike JSRV-LV-injected fetuses of equivalent gestational age, GFP staining was observed in airways between 100 and 225 mm. Although the frequency of airways expressing any GFP was low (12%), an average of 29.9±4.8% of epithelial cells in the positive airways expressed GFP ( Figure 2 ). Similar to JSRV-injected fetuses, GFP expression was observed in interlobule lymphatics, paravertebral lymph nodes, cistern chyli and liver (1-2 cells per cm 2 ). Other fetal organs, fetal membranes, cotyledons and maternal liver were negative for GFP expression.
GP64-, Ebola-pseudotyped LV and AAV2/6.2. GFP immunostaining was absent from fetal lungs and thoracic lymphatics. Except for fetal hepatic transduction (5.6Â10 3 cells per cm 2 ) in the AAV2/6.2-injected fetus, GFP expression was not detected in other fetal organs or the maternal liver.
Airway growth in fetal sheep during the pseudoglandular stage of lung development Lung cross-sectional area, at the midpoint of the right lower lobe, increased from 26 mm 2 at 65 days, to 78 mm 2 at 84 days ( Figure 5 ). Between 65 and 84 days gestational age, airway number within the lung sections increased by 398% (from 769 to 3830), while airway density increased by 68.9% (from 29 to 49 airways per mm 2 ).
DISCUSSION
The primary goal of this study was to determine the capacity of a JSRV-pseudotyped HIV-1-based LV to transduce airway epithelium of fetal sheep during the pseudoglandular stage of lung development. Using GFP expression to assess gene transfer to the fetal lung, we have shown that (1) JSRV-LV efficiently transduced 490% of distal airways (that is future bronchioles) between 20 and 80 mm ID, with an average epithelial transduction of between 16 and 25%, (2) levels of airway epithelial transduction with JSRV-LV were highest when vector was administered earlier in gestation (day 65 versus day 78) and (3) airway epithelial transgene expression was maintained for up to 10 weeks in utero.
A secondary aim of our study was to determine whether viral vectors previously shown to demonstrate tropism for airway epithelium could transduce fetal ovine lung. In mice, intra-amniotic injections of GP64-LV expressing GFP transgene under spleen focus forming virus promoter (1.3-3.0Â10 7 infectious units per fetal sac), at E16, transduced B14% of airway epithelial cells at 2 weeks postinjection. 36 In our current study, high titer GP64-LV (6.6Â10 9 viral particles in 500 ml) directly administered to the fetal airways at day 65 of gestation, did not transduce pulmonary epithelium on assessment 8 days postinjection. Similarly, LV pseudotyped with the glycoproprotein envelope from the Zaire strain of Ebola transduced B30% of the adult murine epithelium, including submucosal glands, when examined at 4 weeks after intra-tracheal injection (5Â10 7 -5Â10 8 transduction units). 38 Intra-tracheal administration of Ebola Zaire-LV (6.9Â10 9 in 300 ml) during the pseudoglandular stage of lung development in a fetal sheep, failed to transduce airway epithelium when assessed at 3 weeks postinjection as evidenced by lack of pulmonary GFP expression. Absence of appropriate cell-surface receptors for Ebola-and GP64-LV may explain their inability to transduce fetal ovine airways. It is also conceivable that the chemical composition of fetal lung fluid may impair transduction of fetal airways. Unlike cell culture mediums, which are optimized to achieve efficient viral vector transduction in vitro, ovine fetal lung fluid is mildly acidic (pHB6.27), hyperchloremic (157 mEq l À1 ) and contains little bicarbonate (2.8 mEq l À1 ) 42 or oxygen. In contrast, low extracellular pH is required for fusion of the JSRV envelope to HYAL2 (ref. 43); thus the low pH of fetal lung fluid may favor airway transduction by JSRV-LV.
Intra-tracheal administration of viral vector did not constrain transgene expression to the lung epithelium. For two of the LVs examined (JRSV-LV and VSVg-LV), extrapulmonary GFP expression Gestational age in the flock from which ewes were selected is estimated at 147 days. LV titers (viral particles per ml) determined by P24 ELISA (viral particles per ml); AAV titer (genome copies per ml) is determined by qPCR. Airway (Aw), pulmonary interlobular lymphatics (pil), paravertebral lymph nodes (pln), cysterna chyli (cc), liver (liv), thymus (thy), heart (hrt), diaphragm (diap), kidney (kid), quadricep muscle (mus), brain (br), spinal cord (cord), gonads (gnd), amniotic membrane (am), placentomes (plac) and maternal liver (ma.liv).
was observed within the pulmonary-systemic lymphatic systems and fetal liver. While AAV2/6.2 did not transduce fetal lung, significant hepatic transduction was observed following intra-tracheal administration. Transepithelial passage of viral vector, from airway lumen to pulmonary lymphatics, or epithelial barotrauma associated with injection volume overload, are potential pathways for systemic entry of vector from the fetal lung lumen. However, during the midpseudoglandular stage of lung development in sheep, functional epithelial tight junctions are impermeable to macro molecules with a molecular radius of over 3.5 nm. 11 As the radii of LVs (40-50 nm) and AAVs (10 nm) are well beyond that which can permeate the intact fetal lung epithelium, transepithelial passage via tight junctions is unlikely. In our current study, an injection volume of 500 ml was chosen for studies at day 65 of gestation. At this age, the volume of fluid within the airway lumen, based upon functional 11 and morphological estimates 10 is B300 ml. Attempts to aspirate fetal lung fluid before vector injection were unsuccessful, and hence following vector injection, airway volume would have more than doubled, from B300 to B800 ml. Given the low distensibility of the fetal lung, 44 a rapid increase in luminal volume would be expected to compromise the structural integrity of the fetal lung epithelium. Additional studies, using lower injections volumes, are required to determine whether an intra-tracheal injection strategy can limit transgene expression to the fetal airways. Our fetal sheep studies were designed to optimize transduction of the lung epithelium. We maximized the concentration of viral vector within the fetal airways by limiting the dilution of vector with fetal lung fluid. Whereas the volume of fetal lung fluid is B300 ml at day 65, it rapidly increases B10-fold (to B3 ml) at day 84. 10, 11 Thus, intratracheal injection of the same volume of vector is diluted to a lesser extent by fetal lung fluid in the younger fetus; although aspiration of fetal lung fluid before vector injection would minimize the dilution effect, this was not technically possible. Another advantage of performing lung gene transfer at day 65 is that, during pseudoglandular stage of lung development, there is an enormous expansion of the respiratory epithelium. In this study, we report that, between day 65 and day 84, fetal airway number and surface area increases by B400 and 127%, respectively. Ideally, we would prefer to perform injections earlier than day 65 to access a higher proportion of stem/progenitor cells, although this is technically challenging. In addition, as transduction time is related to transduction efficiency of LVs, 45 we performed two fetal tracheal occlusion maneuvers to maximize the time of exposure of the epithelium to viral vector; (1) distal to the injection site to prevent vector escaping through the larynx during injection and (2) proximal to the injection site to prevent leakage of vector after removing the angiocatheter. Without tracheal occlusion, lung fluid continually secreted by the pulmonary epithelium would flush vector from the airways into amniotic fluid. During the pseudoglandular stage of lung development in sheep, the volume of fluid within the airway is replaced every hour; assuming a luminal volume of 300 ml and a secretion of fetal lung fluid of 0.3 ml per hour. 11 In our experience, optimal transduction time of 293T cells with JSRV-and VSVg-LV requires a minimum of 48 h. Previous sheep studies that examined retroviral gene transfer to the fetal lung did not occlude the fetal trachea at the time of intra-tracheal vector administration, which may explain, in part, limited transduction of airway epithelium compared with that of our current sheep study. 32, 46 Another potential advantage of performing tracheal occlusion following intra-tracheal administration of vector is to enhance epithelial transduction via increased proliferation. Fetal tracheal occlusion rapidly increases lung epithelial proliferation, 47 while increased cell cycling has been shown to enhance lentiviral transduction in vivo. 48 Clinically, fetal tracheal occlusion following lung vector delivery may be feasible using a reversible balloon tracheal occlusion strategy like that used to treat human fetuses with severe congenital diaphragmatic hernia. 49 Development of a lung-targeting viral vector (that is JSRV-LV) was a third strategy we employed to improve transduction efficiency in fetal sheep. JSRV utilizes the surface receptor HYAL2 (ref. 39) for cell entry, which is highly expressed during the pseudoglandular stage in sheep lung (Figure 1) , and located predominantly on the apical airway surface of distal fetal airways. In contrast, VSVg-mediated cell entry is thought to occur via airway epithelial receptors located on the basolateral cell surface. 35 Although our data are from a limited number of animals, our data support the premise that efficient fetal lung transduction can be achieved using viral vectors pseudotyped to target apical cell-surface receptors.
An intriguing result of the JSRV-LV studies was the absence of GFP transgene expression in major airways. While strong immunostaining of HYAL2, the target receptor for JSRV, 39 was observed within epithelium of trachea and major bronchi, only ciliated epithelium stained positive. The state of differentiation of airway epithelium, specifically the presence or absence of apical cilia, may have an important role in determining transduction efficiency of viral vectors. In vitro studies of cultured human airway epithelia demonstrate that, compared with mature ciliated airway cells, highest levels of adenoviral transduction are achieved using undifferentiated, non-ciliated, epithelium. 3 Thus, cilia appear to function as physical barrier, preventing interaction of viral vectors with their cell-surface receptors. During the pseudoglandular stage of lung development in fetal sheep (40-80 days), maturation of airway epithelium develops centrifugally, with cilia present on major airways as early as day 55. 10 It is therefore conceivable that in our day 65 fetal sheep, cilia present on major airways prevented JRSV-LV from binding to apical HYAL2 receptors. Another interesting observation was that VSVg-LV transduced larger airways than JSRV-LV (o255 mm ID versus o100 mm, respectively), suggesting that differences in vector tropism for fetal ovine airway epithelium exist during mid-gestation. Whereas AAV2/6.2 transduces murine fetal lung during the canalicular stage of lung development (E18), 40 we demonstrate that the same vector is unable to transduce mid-gestation fetal sheep lung. Absence of appropriate AAV airway cell-surface receptors during early fetal life may underlie the lack of GFP expression in the fetal sheep. Additional studies in older fetal sheep would be required to test this hypothesis.
We acknowledge that the small number of fetuses per group is a limitation of our current study, which prevents rigorous statistical comparisons between animal groups. The high cost associated with long-term studies in pregnant sheep and production of large volumes of viral vector preclude higher numbers per group. Although our results should be interpreted with caution, due to small number of experimental animals, our data support the premise that in utero lung gene transfer using lung-targeting LVs can achieve high levels of pulmonary gene expression, which is maintained for up to 10 weeks. Life-long transduction of airway stem cells following intraamniotic delivery of LV has been successful in mice, 27 warranting longer-term studies (that is postnatal) in our sheep model using JSRVand VSVg-LV and minimally invasive methods of temporary fetal tracheal occlusion. Reversible balloon tracheal occlusion 49 is a potential strategy that could be applied to our fetal sheep lung gene transfer model to enable long-term postnatal studies. Serum samples were not obtained from animals in this study and hence we are unable to evaluate immune responses to viral capsid and/or transgene as has been eloquently performed by others using AAV vectors. 15, 50 Figure 4 GFP immunostaining of paravertebral lymph nodes (a; bar¼200 mm) and (b; bar¼50 mm) and interlobular pulmonary lymphatics (c; bar¼50 mM) from fetal sheep (at day 85) following intra-tracheal injection with JSRV-LV at day 65. Hepatic transduction (d; bar¼50 mm) at day 85 following intratracheal injection of AAV6.2 at day 65.
Microscopic examination of the JSRV-and VSVg-LV-injected lungs (performed by EDR) revealed no evidence of inflammatory response. Neither neutrophils nor macrophages were observed in the air spaces or interstitial tissues. The latter only included stromal cells and very rare hematopoietic cells or lymphocytes. Our ongoing studies in postnatal lambs that received intra-tracheal injections of JSRV-and VSVg-LV will determine whether immunological tolerance to transgene can be achieved via an in utero approach.
Fetal lung gene transfer can overcome many of the physical and immunological barriers that have limited the success of postnatal clinical trials, and has the potential to preemptively cure prenatally diagnosed lung diseases before the onset of irreversible tissue damage. The recognized safety concerns of integrating viral vectors, 51 for both fetus and mother, must be addressed before clinical application. Furthermore, it remains to be determined whether lentiviral gene transfer to the fetal lung achieves life-long and therapeutic levels of transduction. In this proof-of-principle study, we have shown that efficient and sustained levels of transgene can be achieved following administration of viral vector designed to target apical surface receptors.
MATERIALS AND METHODS
Experimental protocols were approved by the local Institutional Animal Care and Use Committee and followed the guidelines set forth in the National Institute of Health, Guide for the Care and Use of Laboratory Animals. Figure 5 Airway growth during the pseudoglandular stage of fetal lung development. In fetal sheep, airway density increased from 29.1 to 49.1 airway per mm 2 between day 65 and day 84, respectively (bar¼200 mm). As expected, 10 during the pseudoglandular stage of lung development, dichotomous airway branching gives rise to more numerous, smaller airways that are the future respiratory bronchioles.
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Surgical procedures
Time-dated pregnant ewes of mixed breed underwent aseptic surgery between 65 and 78 days of gestation (term B145 days). Following induction of general inhalation anesthesia, a midline laparotomy was performed and the upper torso of the fetus was exposed via a small hysterotomy. 47 The fetal trachea was isolated, and ligated below the larynx with prolene suture. A 19G angiocatheter was inserted (B1 cm) into the trachea toward the lung lumen. Viral vector was injected at a rate of 1 ml per minute into the tracheal lumen (see Table 1 ), following which the angiocatheter was removed and a second tracheal ligation positioned below the injection site was performed to prevent leakage from the needle puncture site. Following closure of the fetal and maternal incisions, ewes were returned to their pens.
Postmortem
Between 7 and 71 days postinjection, ewes and fetuses were euthanized by intravenous barbiturate overdose; fetal tracheal occlusion was confirmed in each fetus, then lungs and other major fetal organs were harvested for analysis of GFP biodistribution using fluorescent stereomicroscopy (MZ16FA; Leica, Heerburg, Switzerland) equipped with a GFP-bandpass filter (excitation 546/ 10 nm; emission 590 nm) and a triple (Rhodamin, Alexa 546, Texas Red) redchannel filter set for detection of autofluorescence; whole-organ fluorescent images ( Figure 3) are composites of the GFP and red channels. Lungs were pressure fixed with formalin via the trachea to a distending pressure of 20 cmH20 as described elsewhere. 47 Other fetal organs including heart, diaphragm, paravertebral lymph nodes, cysterna chyli, liver, kidney, spleen, gonads, muscle (quadricep), skin, brain and spinal cord, and amniotic membrane, placentomes (5-8 per fetus) and maternal liver were sectioned and submersion fixed in 10% formalin.
HYAL2 ontology in ovine lung
Fetal lung HYAL2 expression at 80, 100, 120, 130 and 145 days gestation, and from 1-day-old lambs, was determined by immunoblotting; Professor Keller Wood (University of Florida, USA) kindly provided nitrocellulose membranes loaded with 50 mg total protein per lane. 52 Membranes were blocked with 5% fat-free milk in TBS (1 h, room temperature), incubated overnight at 4 1C with primary HYAL2 antibody (1:1000; Abcam, Cambridge, MA, USA), rinsed in TBS-T and incubated at room temperature with secondary donkey anti-rabbit horseradish peroxidaseconjugated antibody (1:10 000; GE Healthcare, Piscataway, NJ, USA) for 2 h. Immunoblots were developed using a chemiluminescent substrate kit (SuperSignal West Pico, Pierce, Rockford, IL, USA) and the relative densities of HYAL2 bands were calculated (Scion Image, Bethesda, MD, USA; http://www.scioncorp.com). To account for minor differences in total protein loading, membranes were stripped and re-probed for mouse anti-actin antibody (Abcam). Densiotometric data are expressed as HYAL2 relative to/b-actin.
Immunohistochemistry
Paraffin sections (4 mm) of whole lung from the right lower lobe and proximal conducting airways from the left lung were deparaffinized in serial xylene washes followed by rehydration through a graded series of alcohol series to deionized water. To quench autofluorescence caused by free aldehydes, slides were washed in sodium borohydride-phosphate-buffered saline (PBS) (1 mg ml À1 of sodium borohydride, Sigma (St Louis, MO, USA), in 1% PBS) for 15 min. After rinsing in PBS, slides were blocked with 10% normal goat serum in PBS with 0.2% triton for 30 min at room temperature before incubating overnight (4 1C) with primary antibody (GFP; Invitrogen, Carlsbad, CA, USA; HYAL2; Abcam) at 1:200 in PBS. Slides were then washed with PBS and endogenous peroxidase blocked with S-2001 (Dako, Carpinteria, CA, USA) for 30 min at room temperature. Slides were rinsed with PBS and incubated with biotinylated goat anti-rabbit IgG (1:200 dilution; Vector Lab PK-4001, Vector Labs, Burlingame, CA, USA) for 30 min at room temperature. After rinsing in PBS, slides were incubated with avidin-biotin complex (1:200; Vector Labs) for 30 min at room temperature. Tissues were lightly counterstained using Harris hematoxylin, dehydrated and mounted using Permount (Fisher Scientific, Pittsburgh, PA, USA, Cat# SP15-500). To demonstrate antibody specificity, lung sections from JSRV-and VSVg-LV-injected fetuses underwent the complete immunostaining protocol with omission of either the primary or secondary antibody (Figures 2e-i, respectively) .
Quantitative stereology
Airway epithelial GFP expression. In mid-gestation fetal sheep (60-85 days), airways are readily identifiable as epithelial-lined tubes embedded in mesenchymal tissue ( Figure 5 ). For the late-gestation fetal sheep examined in this study (136 days; n¼2), airways were identified based upon confirmation of an accompanying pulmonary artery. Airway epithelial GFP expression of immunoperoxidase-stained lung sections were evaluated via light microscopy (Leica DMRD) at a final magnification between Â100 and Â400. A radial grid 53 was used to calculate internal airway diameter (ID) and percentage of GFP-positive epithelium. Airways were excluded from analysis if measurements of shortest and longest diameter differed by 425%; thus, only airway that were approximately round in shape were included. The grid was comprised of concentric circles and 24 radial lines. The number of radial lines that intersected a GFP-positive epithelial cell was summed then divided by 24 to obtain percent epithelium transduced. Two non-adjacent sections from the right lower lobe provided a tissue area between 2 and 5 cm 2 for analysis.
Airway growth in fetal sheep during the pseudoglandular stage of lung development. Transverse sections (4 mm) were obtained at the midpoint of the lower right lobe from a normally grown (that is no fetal intervention) 65 days and an 84-day fetal sheep and stained with hematoxylin and eosin. Digital lung images were obtained at Â5 magnification and combined to provide a high-resolution montage of the entire lung section. Airway number and diameter and area of the section were measured (SigmaScan Pro Version 5.0, SysStat Software Inc., Chicago, IL, USA ); airways were excluded from analysis if minimum and maximum diameter differed by 425%.
Data analysis
Epithelial GFP expression and HYAL2 densitometry data are presented as the mean±s.e.m. For airway growth analysis in normally grown fetal sheep at 65 and 85 days, airways were arbitrarily binned according to ID (0-9.99, 10.00-14.99, 15.00-19.99, 20.00-24.99, 25.00-29.99, 30.00-39.99, 40.00-99.99, 100.00-199.99, 200.00-499.99, 500.00-1000.00 mm); average airway diameter for each of the bin categories was calculated and plotted against frequency, as a percentage of total airway number. To provide an estimate of airway density (airway number per mm 2 ), total airway number was divided by area of the lung section.
Viral vectors
The CS-CG lentivector plasmid backbone, kindly provided by Dr Inder Verma, 54 was modified to improve safety, prevent mobilization and deleted of unnecessary viral sequences to increase the transgene cassette capacity. 24 The lentivector transfer plasmid contained the enhanced GFP reporter (Clontech Laboratories, Mountain View, CA, USA) under the control of the CMV promoter. The GP64 was cloned from the Autographa californica derived AcMNP baculovirus plasmid. 55 The coding sequence for the Ebola envelope was kindly obtained from the Centers for Disease Control and Prevention and the constructed cDNA molecule was deleted of the region of O-glycosylation, the mucin-like region. 56 The JSRV envelope was kindly obtained from Dr A Dusty Miller. 57 LVs were generated by transient co-transfection of 293T cells with the packaging, transfer and envelope plasmids. 26 Titer of all LV was determined by p24 antigen ELISA (Center for AIDS Research, The University of Pennsylvania, Philadelphia, PA, USA). Titer of AAV2/6.2 was determined via qPCR using a primer set matching the polyadenylation signal in the vector genome as previously described. 41 
